PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma

Cancer Treatment Reviews

Volumn 41, Issue 8, 2015, Pages 707-713

  Petrulea, Mirela S ^a   Plantinga, Theo S ^b   Smit, Jan W ^b   Georgescu, Carmen E ^a   Netea Maier, Romana T ^b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Akt; MTOR; PI3K; Therapy resistance; Thyroid carcinoma; Tumorigenesis

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 8 (6 METHOXY 3 PYRIDINYL) 3 METHYL 1 [4 (1 PIPERAZINYL) 3 (TRIFLUOROMETHYL)PHENYL] 1H IMIDAZO[4,5 C]QUINOLIN 2(3H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; APITOLISIB; CHIR 265; DACTOLISIB; EVEROLIMUS; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PASIREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; RAPAMYCIN; SELUMETINIB; SORAFENIB; TEMSIROLIMUS; VOXTALISIB; NUCLEAR PROTEIN; PI3KCA PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR;

CYTOTOXICITY; DIFFERENTIATED THYROID CANCER; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; NON-MEDULLARY THYROID CARCINOMA; NONHUMAN; PATHOGENESIS; POINT MUTATION; PROTEIN FUNCTION; REVIEW; SOMATIC MUTATION; THYROID CARCINOMA; CARCINOGENESIS; CARCINOMA; DISEASE MANAGEMENT; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRENDS;

CARCINOGENESIS; CARCINOMA; DISEASE MANAGEMENT; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 84941023564     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.06.005     Document Type: Review

References (101)

1. Pacini F., Castagna M.G., Brilli L., Pentheroudakis G., Group E.G.W. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):V214-v219.
2. Brose M.S., Smit J., Capdevila J., Elisei R., Nutting C., Pitoia F., et al. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Exp Rev Anticancer Ther 2012, 12:1137-1147.
3. Cooper D.S., Doherty G.M., Haugen B.R., Hauger B.R., Kloos R.T., Lee S.L., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
4. Schneider T.C., Abdulrahman R.M., Corssmit E.P., Morreau H., Smit J.W.A., Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012, 167:643-650.
5. Brose M.S., Nutting C.M., Jarzab B., Elisei R., Siena S., Bastholt L., et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014, 384:319-328.
6. Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrin Metab 2006, 91:2892-2899.
7. Monchik J.M., Donatini G., Iannuccilli J., Dupuy D.E. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 2006, 244:296-304.
8. Vogl T.J., Lehnert T., Zangos S., Eichler K., Hammerstingl R., Korkusuz H., et al. Transpulmonary chemoembolization (TPCE) as a treatment for unresectable lung metastases. Eur Radiol 2008, 18:2449-2455.
9. Sherman S.I. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010, 22:464-468.
10. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013, 13:184-199.
11. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63:1454-1457.
12. Soares P., Trovisco V., Rocha A.S., Lima J., Castro P., Preto A., et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22:4578-4580.
13. Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003, 95:625-627.
14. Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W., Tallini G., et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003, 88:2318-2326.
15. Dwight T., Thoppe S.R., Foukakis T., Lui W.O., Wallin G., Hoog A., et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 2003, 88:4440-4445.
16. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science (New York, N.Y.) 2000, 289:1357-1360.
17. Hou P., Liu D., Shan Y., Hu S., Studeman K., Condouris S., et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007, 13:1161-1170.
18. Garcia-Rostan G., Costa A.M., Pereira-Castro I., Salvatore G., Hernandez R., Hermsem M.J.A., et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005, 65:10199-10207.
19. Hou P., Ji M., Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 2008, 113:2440-2447.
20. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
21. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010, 20:697-706.
22. Saji M., Ringel M.D. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 2010, 321:20-28.
23. Fingar D.C., Salama S., Tsou C., Harlow E., Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002, 16:1472-1487.
24. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
25. Kumar D., Shankar S., Srivastava R.K. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway. Cancer Lett 2014, 343:179-189.
26. Cantley L.C. The phosphoinositide 3-kinase pathway. Science (New York, N.Y.) 2002, 296:1655-1657.
27. Markman B., Atzori F., Perez-Garcia J., Tabernero J., Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010, 21:683-691.
28. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28:1075-1083.
29. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (New York, N.Y.) 2005, 307:1098-1101.
30. Bhaskar P.T., Hay N. The two TORCs and Akt. Dev Cell 2007, 12:487-502.
31. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
32. Asnaghi L., Calastretti A., Bevilacqua A., D'Agnano I., Gatti G., Canti G., et al. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004, 23:5781-5791.
33. Zeng X., Kinsella T.J. Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy. Cancer Res 2008, 68:2384-2390.
34. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
35. Sarbassov D.D., Ali S.M., Sabatini D.M. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005, 17:596-603.
36. Santoro M., Dathan N.A., Berlingieri M.T., Bongarzone I., Paulin C., Grieco M., et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994, 9:509-516.
37. Castellone M.D., De Falco V., Rao D.M., Bellelli R., Muthu M., Basolo F., et al. The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res 2009, 69:1867-1876.
38. Miller K.A., Yeager N., Baker K., Liao X.-H., Refetoff S., Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 2009, 69:3689-3694.
39. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
40. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
41. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998, 273:13375-13378.
42. Dahia P.L., Marsh D.J., Zheng Z., Zedenius J., Komminoth P., Frisk T., et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 1997, 57:4710-4713.
43. Bruni P., Boccia A., Baldassarre G., Trapasso F., Santoro M., Chiappetta G., et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000, 19:3146-3155.
44. Eberhardt N.L., Grebe S.K.G., McIver B., Reddi H.V. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol 2010, 321:50-56.
45. Diallo-Krou E., Yu J., Colby L.A., Inoki K., Wilkinson J.E., Thomas D.G., et al. Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology 2009, 150:5181-5190.
46. Wang Y., Hou P., Yu H., Wang W., Ji M., Zhao S., et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrin Metab 2007, 92:2387-2390.
47. Wu G., Mambo E., Guo Z., Hu S., Huang X., Gollin S.M., et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 2005, 90:4688-4693.
48. Ringel M.D., Hayre N., Saito J., Saunier B., Schuppert F., Burch H., et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001, 61:6105-6111.
49. Vasko V., Saji M., Hardy E., Kruhlak M., Larin A., Savchenko V., et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 2004, 41:161-170.
50. Liu Z., Hou P., Ji M., Guan H., Studeman K., Jensen K., et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008, 93:3106-3116.
51. Santoro M., Papotti M., Chiappetta G., Garcia-Rostan G., Volante M., Johnson C., et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 2002, 87:370-379.
52. Nikiforov Y.E. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008, 21(2):S37-S43.
53. Volante M., Rapa I., Gandhi M., Bussolati G., Giachino D., Papotti M., et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab 2009, 94:4735-4741.
54. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006, 6:292-306.
55. Zysman M.A., Chapman W.B., Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 2002, 160:795-800.
56. Soria J.-C., Lee H.-Y., Lee J.I., Wang L., Issa J.-P., Kemp B.L., et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002, 8:1178-1184.
57. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16:64-67.
58. Kim C.S., Vasko V.V., Kato Y., Kruhlak M., Saji M., Cheng S.-Y., et al. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 2005, 146:4456-4463.
59. Furuya F., Hanover J.A., Cheng S.-y. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci USA 2006, 103:1780-1785.
60. Furuya F., Lu C., Willingham M.C., Cheng S.-Y. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 2007, 28:2451-2458.
61. Guigon C.J., Fozzatti L., Lu C., Willingham M.C., Cheng S.-Y. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis 2010, 31:1284-1291.
62. Burrows N., Telfer B., Brabant G., Williams K.J. Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity. Radiother Oncol 2013, 108:548-553.
63. Burrows N., Babur M., Resch J., Ridsdale S., Mejin M., Rowling E.J., et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1alpha (HIF-1alpha) pathways. J Clin Endocrinol Metab 2011, 96:E1934-E1943.
64. Hassan B., Akcakanat A., Holder A.M., Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am 2013, 22:641-664.
65. Fasolo A., Sessa C. MTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008, 17:1717-1734.
66. Brewer C., Yeager N., Di Cristofano A. Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res 2007, 67:8002-8006.
67. Yeager N., Brewer C., Cai K.Q., Xu X.-X., Di Cristofano A. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res 2008, 68:444-449.
68. Papewalis C., Wuttke M., Schinner S., Willenberg H.S., Baran A.M., Scherbaum W.A., et al. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm Metab Res 2009, 41:752-756.
69. Behlendorf T.V.W., Mueller T., Jordan K., Arnold D., Schmoll H. Activity of mTOR-inhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines. J Clin Oncol 2009, 27:e14608.
70. Ogita S., Lorusso P. Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Targeted Oncol 2011, 6:103-117.
71. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
72. Janes M.R., Vu C., Mallya S., Shieh M.P., Limon J.J., Li L.S., et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia 2013, 27:586-594.
73. Ahmed M., Hussain A.R., Bavi P., Ahmed S.O., Al Sobhi S.S., Al-Dayel F., et al. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. Carcinogenesis 2014, 35:1564-1572.
74. Lim S.M., Chang H., Yoon M.J., Hong Y.K., Kim H., Chung W.Y., et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol 2013, 24:3089-3094.
75. Lorch J. A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). J Clin Oncol 2013.
76. Wagle N., Grabiner B.C., Van Allen E.M., Amin-Mansour A., Taylor-Weiner A., Rosenberg M., et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014, 371:1426-1433.
77. Maira S.-M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863.
78. Lin S.-F., Huang Y.-Y., Lin J.-D., Chou T.-C., Hsueh C., Wong R.J. Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS ONE 2012, 7:e46726.
79. Liu R., Liu D., Trink E., Bojdani E., Ning G., Xing M. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab 2011, 96:E577-E585.
80. Liu D., Hou P., Liu Z., Wu G., Xing M. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009, 69:7311-7319.
81. Jin N., Jiang T., Rosen D.M., Nelkin B.D., Ball D.W. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009, 94:4107-4112.
82. Kandil E., Tsumagari K., Ma J., Abd Elmageed Z.Y., Li X., Slakey D., et al. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. J Surg Res 2013, 184:898-906.
83. Jin N., Jiang T., Rosen D.M., Nelkin B.D., Ball D.W. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res 2011, 17:6482-6489.
84. Sherman E., Ho A., Fury M., Baxi S., Haque S., Lipson B., et al. Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer. J Clin Oncol 2013.
85. Brose M., Troxel A., Mamtani R. Phase II trial of everolimus with sorafenib for patients with differentiated thyroid cancer (DTC) who progress on sorafenib alone. J Clin Oncol 2010.
86. Sherman E., Ho A., Fury M., Baxi S., Dunn L., Lee J., et al. Combination of everolimus and sorafenib in the treatment of thyroid cancer: update on phase II study. J Clin Oncol 2015.
87. Brose M., Troxel A., Yarchoan M., Cohen A., Harlacker K., Dyanick N., et al. A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone. J Clin Oncol 2015.
88. Lin C.-I., Whang E.E., Donner D.B., Du J., Lorch J., He F., et al. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res 2010, 8:1217-1226.
89. Chung J.-K., Youn H.W., Kang J.H., Lee H.Y., Kang K.W. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging 2010, 44:4-14.
90. Furuya F., Shimura H., Suzuki H., Taki K., Ohta K., Haraguchi K., et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004, 145:2865-2875.
91. Catalano M.G., Pugliese M., Poli R., Bosco O., Bertieri R., Fortunati N., et al. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib. Oncol Rep 2009, 21:515-521.
92. Shen W.T., Wong T.S., Chung W.-Y., Wong M.G., Kebebew E., Duh Q.-Y., et al. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery 2005, 138:979-984. [discussion 84-5].
93. Luong Q.T., O'Kelly J., Braunstein G.D., Hershman J.M., Koeffler H.P. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 2006, 12:5570-5577.
94. Schmutzler C., Winzer R., Meissner-Weigl J., Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997, 240:832-838.
95. Simon D., Korber C., Krausch M., Segering J., Groth P., Gorges R., et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002, 29:775-782.
96. Kim W.G., Kim E.Y., Kim T.Y., Ryu J.-S., Hong S.J., Kim W.B., et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J 2009, 56:105-112.
97. Liu Y.Y., Stokkel M.P., Pereira A.M., Corssmit E.P., Morreau H.A., Romijn J.A., et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol 2006, 154:525-531.
98. de Souza E.C.L., Padron A.S., Braga W.M.O., de Andrade B.M., Vaisman M., Nasciutti L.E., et al. MTOR downregulates iodide uptake in thyrocytes. J Endocrinol 2010, 206:113-120.
99. Kogai T., Sajid-Crockett S., Newmarch L.S., Liu Y.-Y., Brent G.A. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. J Endocrinol 2008, 199:243-252.
100. Plantinga T.S., Heinhuis B., Gerrits D., Netea M.G., Joosten L.A.B., Hermus A.R.M.M., et al. MTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. J Clin Endocrinol Metab 2014, 99:E1368-E1375.
101. Ho A.L., Grewal R.K., Leboeuf R., Sherman E.J., Pfister D.G., Deandreis D., et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013, 368:623-632.